We are pleased to invite investors and analysts to participate in our virtual event on Friday, 7 February 2025, to highlight Roche’s immunology kidney pipeline and Phase III (REGENCY) Gazyva in lupus nephritis data presented at the World Congress of Nephrology (WCN) 2025 Meeting, from 6 February - 9 February 2025. 16:30 - 17:30 CET / 15:30 - 16:30 GMT 10:30 - 11:30 am EST / 7:30 - 8:30 am PST The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:30 CET on the day of the event. > click here Agenda Introduction Bruno Eschli, Head of Investor Relations Roche immunology kidney pipeline Larry Tsai, Senior Vice President and Global Head of Product Development Immunology Ph III (REGENCY) Gazyva in lupus nephritis data at WCN 2025 Brad H. Rovin, MD, FASN, FACP Q&A Access to virtual event (pre-registration required) Please pre-register for our webinar here*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com. A replay of the webcast will be available via > ir.roche.com *privacy notice Best regards,

Bruno Eschli Head of Investor Relations	Loren Kalm Head of Investor Relations, North America
Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

get the latest news and updates to your inbox.